Drug Database · Clinicians

Fluorometholone

Brands (5) AFM, E-Flo, Eyfem…Show all

US brand (reference label): FML; not a Philippine-registered brand.

Corticosteroid (Corticosteroid Hormone Receptor Agonists) US FDA class
Corticosteroid; Costicosteroid; and others PH FDA category

Rx · Prescription drug5 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c374d65a-35b5-4c9e-9069-5148875dc4df, version date December 1, 2023 (FML · Allergan, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE FML ® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE FML ® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Contraindications

CONTRAINDICATIONS FML ® suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye, and fungal diseases of ocular structures. FML ® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Shake well before using. Instill one drop into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased to one application every four hours. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).

The dosing of FML ® suspension may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in infants below the age of two years have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Dosage forms

Philippines

  • Sterile ophthalmic suspension: 1 mg/mL
  • Ophthalmic suspension: 1 mg/mL

Registered products in the Philippines

5 products registered with the Food and Drug Administration (FDA) Philippines list Fluorometholone as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Flourometholone (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products5
Philippine FDA-registered products for Fluorometholone
Package insert
AFMFluorometholone Acetate
1 mg/ mL (0.1% w/v) Sterile Ophthalmic SuspensionPlastic Dropper Bottle X 5 mL (Box of 1's) Box of 1's
Rx
ARISTOPHARMA LTD.Bangladesh
SAHAR INTERNATIONAL TRADING, INC.
DRP-7033
Dec 18, 2029
E-FloFluorometholone
1 mg/mL (0.1% w/v) Sterile Ophthalmic SuspensionLDPE White Plastic Droptainer in 5mL (net content) (Box of 1's)
Rx
Makcur Laboratories Ltd.India
Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd.
DR-XY49553
Oct 16, 2030
EyfemFlourometholoneVariant spelling
1 mg/mL (0.1% w/v) Sterile Ophthalmic SuspensionLDPE White Plastic Droptainer in 5 mL (net content) (Box of 1's)
Rx
Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan
Phil. Pak Import Export and Trading Corporation
DR-XY46186
Mar 4, 2037
FlarexFluorometholone Acetate
1 mg/mL (0.1%) Ophthalmic SuspensionPlastic Droptainer Dispenser Bottle x 5 mL (Box of 1's)
Rx
Alcon - Couvreur NVBelgium
Importer: Novartis Healthcare Philippines, Inc.
DR-XY13480
Sep 5, 2027
FlulonFluorometholone
1 mg/mL (0.1% w/v) Ophthalmic SuspensionPolyethylene (PE) plastic bottle x 5 mL (net content) Box of 1's
Rx
Santen Pharmaceutical Co., Ltd.Japan
Importer: Santen Philippines Inc.
DR-XY25291
Nov 29, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Prolonged use of corticosteroids may increase intraocular pressure in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical dermatologic steroids applied to the skin.

Corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. The development of secondary ocular infection (bacterial, fungal and viral) has occurred.

Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (see WARNINGS). Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of FML ® suspension.

Other adverse events reported with the use of fluorometholone include: allergic reactions; foreign body sensation; erythema of eyelid; eyelid edema/eye swelling; eye discharge; eye pain; eye pruritus; lacrimation increased; rash; taste perversion; visual disturbance (blurry vision); and visual field defect.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic effects Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed.

There are no adequate and well-controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically-administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.

Because of the potential for serious adverse reactions in nursing infants from fluorometholone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Arachidonic acid is released from membrane phospholipids by phospholipase A 2. Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies of documented steroid-responders, fluorometholone demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate; however, in a small percentage of individuals, a significant rise in intraocular pressure occurred within one week.

The ultimate magnitude of the rise was equivalent for both drugs.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. FML · Allergan, Inc. [US FDA-approved label, version 14, December 1, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c374d65a-35b5-4c9e-9069-5148875dc4df
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .